Welcome to Oxford Medical Diagnostics
Oxford Medical Diagnostics is developing a unique blend of technology that makes it possible to provide rapid, accurate and low-cost diagnosis and monitoring of several diseases and metabolic functions.
Its initial objective is to bring to market a non-invasive at-patient diagnostic instrument to detect type I and II diabetes.
The OMD approach is based on development of breath analysis, potentially a highly accurate method of diagnosis, where it has already achieved significant results. In the case of diabetes, this involves the detection of acetone in the patient’s breath.
The company also has a growing business in industrial gas analysis using its analytical expertise.
Proprietary technologies include Cavity Enhanced Absorption Spectroscopy (CEAS), based on tunable diode lasers, Broadband Cavity Enhanced Absorption Spectroscopy (BBCEAS), which uses a superluminescent light emitting diode, and Plasma Emission Spectroscopy (PES).
Unlike many early-stage technology companies, OMD has already brought together a highly experienced management team whose members have excellent track records of success in company development and technology. The company has raised £1.25 million in funding from its management team and private investors. It maintains close links with the University of Oxford and academics around the world.
Oxford Medical Diagnostics is developing advanced analysis techniques in two markets:
| Please click the icons to learn more. | | |